/APLS
APLS Stock - Apellis Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$24.65+0.69%
+$0.17 (+0.69%) • Dec 19
85
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.78
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+37.9%upside
Target: $33.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for APLS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$24.40 – $24.90
TARGET (TP)$34.00
STOP LOSS$22.68
RISK/REWARD1:4.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.36
52W High$35.57
52W Low$16.10
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $781.37M | $396.59M | $75.42M | $66.56M | $250.65M |
| Gross Profit | $663.64M | $338.08M | $69.79M | $61.36M | $225.60M |
| Gross Margin | 84.9% | 85.2% | 92.5% | 92.2% | 90.0% |
| Operating Income | $-164,979,000 | $-517,121,000 | $-594,613,000 | $-536,277,000 | $-213,726,000 |
| Net Income | $-197,878,000 | $-528,628,000 | $-652,172,000 | $-746,354,000 | $-344,874,000 |
| Net Margin | -25.3% | -133.3% | -864.7% | -1121.3% | -137.6% |
| EPS | $-1.60 | $-4.45 | $-6.15 | $-8.84 | $-4.59 |
Company Overview
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
40%
Hold / Neutral
10
50%
Sell / Underperform
2
10%
Analyst Consensus🔴 Bearish
8 Bullish12 Neutral/Bearish
Price Targets
$49
Average Target
↑ 98.2% Upside
Now
$18
Low
$49
Average
$81
High
Based on 22 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 6th 2025 | Wolfe Research | Initiation | Peer Perform | - |
| October 15th 2025 | Wells Fargo | Initiation | Overweight | $32 |
| September 26th 2025 | Goldman | Downgrade | Sell | $18 |
| May 9th 2025 | Raymond James | Downgrade | Outperform | $52 |
| May 9th 2025 | BofA Securities | Downgrade | Neutral | $23 |
| April 29th 2025 | Cantor Fitzgerald | Initiation | Overweight | $44 |
| December 17th 2024 | Goldman | Downgrade | Neutral | $36 |
| November 21st 2024 | Morgan Stanley | Initiation | Equal Weight | $31 |
| October 25th 2024 | RBC Capital Mkts | Initiation | Sector Perform | $25 |
| October 16th 2024 | Scotiabank | Initiation | Sector Outperform | - |
| October 16th 2024 | William Blair | Initiation | Outperform | - |
| May 31st 2024 | Piper Sandler | Initiation | Neutral | $46 |
| February 5th 2024 | Jefferies | Upgrade | Buy | $80← $68 |
| December 14th 2023 | Wells Fargo | Downgrade | Equal Weight | - |
| November 9th 2023 | Goldman | Initiation | Buy | $74 |
Earnings History & Surprises
APLSBeat Rate
33%
Last 18 quarters
Avg Surprise
-10.6%
EPS vs Estimate
Beats / Misses
6/11
1 met exactly
Latest EPS
$1.67
Q4 2025
EPS Surprise History
Q1 24
-10.6%
$-0.73vs$-0.66
Q2 24
0.0%
$-0.54vs$-0.54
Q3 24
+15.2%
$-0.28vs$-0.33
Q4 24
-43.8%
$-0.46vs$-0.32
Q1 25
+21.6%
$-0.29vs$-0.37
Q2 25
-105.6%
$-0.74vs$-0.36
Q3 25
+25.0%
$-0.33vs$-0.44
Q4 25
+62.1%
$1.67vs$1.03
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 27, 2026 | $-0.41 | — | — | — |
Q4 2025 | Oct 30, 2025 | $1.03 | $1.67 | +62.1% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $-0.44 | $-0.33 | +25.0% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.36 | $-0.74 | -105.6% | ✗ MISS |
Q1 2025 | Feb 28, 2025 | $-0.37 | $-0.29 | +21.6% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $-0.32 | $-0.46 | -43.8% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.33 | $-0.28 | +15.2% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.54 | $-0.54 | 0.0% | = MET |
Q1 2024 | Feb 27, 2024 | $-0.66 | $-0.73 | -10.6% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $-0.84 | $-1.17 | -39.3% | ✗ MISS |
Q3 2023 | Jul 31, 2023 | $-1.35 | $-1.02 | +24.4% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-1.42 | $-1.56 | -9.9% | ✗ MISS |
Q1 2023 | Feb 21, 2023 | $-1.65 | $-1.50 | +9.1% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-1.48 | $-1.75 | -18.2% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-1.43 | $-1.46 | -2.1% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-1.36 | $-1.42 | -4.4% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-1.32 | $-1.61 | -22.0% | ✗ MISS |
Q4 2021 | Nov 8, 2021 | $-1.73 | $-2.28 | -31.8% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-1.70 | $-2.72 | -60.0% | ✗ MISS |
Latest News
Stifel Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $48
➖ NeutralBenzinga•Dec 19, 2025, 02:28 PM•Also:
Apellis Pharmaceuticals Announces The The New England Journal of Medicine Published Phase 3 VALIANT Results For EMPAVELI In C3G And IC-MPGN Patients; Reports Robust And Clinically Meaningful Benefits Across All Three Key Markers Of Disease, 68% Reduction In Proteinuria, Stabilization Of Kidney Function, And Substantial Clearance Of C3 Deposits
📈 PositiveBenzinga•Dec 3, 2025, 10:07 PM
Apellis Pharmaceuticals Data From GALE Extension Trial Of SYFOVRE Demonstrates Delayed Geographic Atrophy Lesion Growth By ~1.5 Years In Patients With Nonsubfoveal GA
📈 PositiveBenzinga•Nov 12, 2025, 12:15 PM
Wolfe Research Initiates Coverage On Apellis Pharmaceuticals with Peer Perform Rating
➖ NeutralBenzinga•Nov 6, 2025, 01:25 PM
JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $36
➖ NeutralBenzinga•Nov 5, 2025, 07:49 PM
Mizuho Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $19
➖ NeutralBenzinga•Nov 3, 2025, 05:57 PM
Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
➖ NeutralBenzinga•Oct 31, 2025, 08:24 PM•Also:
TD Cowen Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
➖ NeutralBenzinga•Oct 31, 2025, 06:01 PM
Baird Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $52
📈 PositiveBenzinga•Oct 31, 2025, 12:24 PM
HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
➖ NeutralBenzinga•Oct 31, 2025, 10:22 AM
Apellis Pharmaceuticals shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Oct 30, 2025, 03:00 PM
Apellis Pharmaceuticals Q3 EPS $1.67 Beats $0.92 Estimate, Sales $458.578M Beat $406.678M Estimate
📈 PositiveBenzinga•Oct 30, 2025, 11:06 AM
Apellis Highlights New Phase 3 Data Showing EMPAVELI Sustains Kidney Function And Proteinuria Reduction In Rare Kidney Diseases
📈 PositiveBenzinga•Oct 20, 2025, 11:13 AM
Apellis Pharmaceuticals shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $29 to $32.
📈 PositiveBenzinga•Oct 15, 2025, 04:17 PM
Wells Fargo Upgrades Apellis Pharmaceuticals to Overweight, Raises Price Target to $32
📈 PositiveBenzinga•Oct 15, 2025, 12:44 PM
Goldman Sachs Downgrades Apellis Pharmaceuticals to Sell, Lowers Price Target to $18
📉 NegativeBenzinga•Sep 26, 2025, 04:51 PM
Frequently Asked Questions about APLS
What is APLS's current stock price?
Apellis Pharmaceuticals, Inc. (APLS) is currently trading at $24.65 per share. The stock has moved +0.69% today.
What is the analyst price target for APLS?
The average analyst price target for APLS is $34.00, based on 1 analyst.
What sector is Apellis Pharmaceuticals, Inc. in?
Apellis Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is APLS's market cap?
Apellis Pharmaceuticals, Inc. has a market capitalization of $3.12 billion, making it a mid-cap company.
Does APLS pay dividends?
No, Apellis Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADPT
Adaptive Biotechnologies Corporation
$17.00
Mkt Cap: $2.6B
AGIO
Agios Pharmaceuticals, Inc.
$24.46
Mkt Cap: $1.4B
BEAM
Beam Therapeutics Inc.
$26.57
Mkt Cap: $2.7B
CDTX
Cidara Therapeutics, Inc.
$220.80
Mkt Cap: $5.6B
CPRX
Catalyst Pharmaceuticals, Inc.
$23.74
Mkt Cap: $2.9B
IDYA
IDEAYA Biosciences, Inc.
$33.55
Mkt Cap: $2.9B
KNSA
Kiniksa Pharmaceuticals, Ltd.
$43.19
Mkt Cap: $3.2B
MLYS
Mineralys Therapeutics, Inc.
$36.83
Mkt Cap: $2.4B
RXRX
Recursion Pharmaceuticals, Inc.
$4.26
Mkt Cap: $1.7B
SRRK
Scholar Rock Holding Corporation
$43.90
Mkt Cap: $4.5B
Explore stocks similar to APLS for comparison